Irbesartan Macleods Pharma Uk

Irbesartan, the active ingredient in Irbesartan Macleods Pharma Uk, is an angiotensin II receptor blocker presented as an oral dosage form for oral use. It is employed to treat high blood pressure and to protect kidney function in patients with diabetic kidney disease.

GNH USA supplies Irbesartan Macleods Pharma Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global logistics.

Irbesartan acts on the renin‑angiotensin system to manage cardiovascular and renal conditions.

- Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack. - Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes, decreasing proteinuria. - Chronic kidney disease with hypertension: helps control blood pressure and limits further renal decline.

Irbesartan may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Dizziness - Headache - Fatigue

Serious or Rare Side Effects: - Angioedema - Hyperkalemia - Acute renal failure

When prescribing Irbesartan, clinicians should consider several safety measures.

- Monitor blood pressure regularly: ensure therapeutic targets are achieved without excessive hypotension. - Assess renal function before and during therapy: watch for changes in serum creatinine. - Check serum potassium levels: avoid hyperkalaemia, especially with concomitant potassium‑sparing agents. - Avoid use during pregnancy: drug is classified as Category D and may cause fetal harm. - Use caution in hepatic impairment: dose adjustments may be required. - Store at room temperature: keep in the original pack, protect from moisture.

Irbesartan can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes): combined use may increase risk of renal impairment. - ACE inhibitors: additive effects on potassium and renal function. - Potassium‑sparing diuretics: may precipitate hyperkalaemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: can enhance the antihypertensive effect, risking hypotension. - Cyclosporine: may increase plasma concentrations of irbesartan. - Rifampin: may reduce irbesartan levels, diminishing efficacy.